SRP3173

TIMP-1 human

recombinant, expressed in E. coli, ≥95% (SDS-PAGE), ≥95% (HPLC), suitable for cell culture

• Synonim(y): Erythroid-Potentiating activity, Fibroblast collagenase inhibitor, Tissue inhibitor of metalloproteinase
• NACRES: NA.32
• UNSPSC Code: 12352200
• Form: lyophilized
• Assay: ≥95% (HPLC), ≥95% (SDS-PAGE)
• Biological source: human
• Recombinant: expressed in E. coli
• Mol wt: 20.6 kDa

Właściwości

• biological source: human
• recombinant: expressed in E. coli
• assay: ≥95% (HPLC), ≥95% (SDS-PAGE)
• form: lyophilized
• potency: 0.5 μg/mL
• mol wt: 20.6 kDa
• packaging: pkg of 10 μg
• technique(s): cell culture | mammalian: suitable
• impurities: <0.1 EU/μg endotoxin, tested
• color: white
• suitability: suitable for molecular biology
• UniProt accession no.: P01033
• shipped in: wet ice
• storage temp.: −20°C
• Gene Information: human ... TIMP1(7076)

Opis

General description

Research area: Cell SignalingTIMP1 (tissue inhibitor of metalloproteinase 1) is a glycoprotein and belongs to the TIMP family of endogenous MMP (matrix metalloproteinase) inhibitors. Humans contain four TIMPs. All TIMPs contain an N-terminal of 125 residues, a 65-residue C-terminal, and both these domains with three disulfide bonds. The N-terminal domain inhibits MMPs by folding into a separate unit. Recombinant human TIMP-1 is a 20.6 kDa protein containing 184 amino acid residues.

Application

TIMP-1 human has been used for inhibition assays in enzymatic activity assays of Mmp1-CD and Mmp2-CD. It has also been used in interaction immunoassay.

Biochem/physiol Actions

TIMP1 functions as a poor inhibitor of MT1 (membrane type 1)-MMP, MT3-MMP, MT5-MMP and MMP-19. It inhibits ADAM10 (a disintegrin and metalloproteinase domain-containing protein 10) protein. In HUVECs, the down-regulation of TIMP1 and up-regulation of MMP-3 results in aberrant endothelium-dependent vasodilation, EC (endothelial cell) death, and endothelial interruption in a FOXO3 (forkhead box O3)-mediated manner. In patients with CAD (coronary artery disease) and acute coronary syndrome (ACS), the urine levels of this protein are elevated. This protein interacts with Bcl-2 (B cell lymphoma) protein, and induces apoptosis in lung adenocarcinoma cells. The plasma levels of this protein are increased in patients with obesity and obesity-related disorders, such as steatosis, where it participates in pathogenesis of diet-induced hepatic steatosis and glucose intolerance.

Physical form

Lyophilized from 10 mM Sodium Phosphate, pH 7.5.

Preparation Note

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

Other Notes

CTCVPPHPQT AFCNSDLVIR AKFVGTPEVN QTTLYQRYEI KMTKMYKGFQ ALGDAADIRF VYTPAMESVC GYFHRSHNRS EEFLIAGKLQ DGLLHITTCS FVAPWNSLSL AQRRGFTKTY TVGCEECTVF PCLSIPCKLQ SGTHCLWTDQ LLQGSEKGFQ SRHLACLPRE PGLCTWQSLR SQIA

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable